MARTIN J TYLER 4
4 · DYNAVAX TECHNOLOGIES CORP · Filed Feb 14, 2012
Insider Transaction Report
Form 4
MARTIN J TYLER
VP Clinical Development & CMO
Transactions
- Award
Common shares
2012-02-13$0.58/sh+150,000$87,000→ 150,000 total - Award
Common shares
2012-02-13$1.72/sh+32,848$56,499→ 182,848 total - Exercise/Conversion
Option (Right to Buy)
2012-02-13−75,000→ 225,000 totalExercise: $0.58From: 2010-02-27Exp: 2019-02-26→ Common Stock (75,000 underlying) - Exercise/Conversion
Options (Right to Buy)
2012-02-13−75,000→ 150,000 totalExercise: $0.58From: 2011-02-27Exp: 2019-02-26→ Common Stock (75,000 underlying) - Exercise/Conversion
Options (Right to Buy)
2012-02-13−32,848→ 484,396 totalExercise: $1.72From: 2011-08-25Exp: 2020-08-24→ Common Stock (32,848 underlying)
Footnotes (2)
- [F1]Not applicable.
- [F2]On February 13, 2012, Dr. Martin exercised certain of his outstanding options for cash. No shares were sold in the market in connection with this exercise.